| Literature DB >> 26690115 |
Wei Zhou1,2,3,4, Baochang Cai5,6, Jinjun Shan7, Shouchuan Wang8, Liuqing Di9,10,11,12.
Abstract
Traditional Chinese medicines (TCMs) have attracted extensive interest throughout the world due to their long history of health protection and disease control, and the internalization of TCM preparations or patented drugs has been considered a wind vane in the process of TCM modernization. However, multi-target effects, caused by multiple components in TCMs, hinder not only the construction of the quality evaluation system (bioavailability), but also the application of pharmaceutical technologies, which results in the poor efficacy in clinical practice. This review describes the methods in the literature as well as in our thoughts about how to identify the marker components, establish the evaluation system of bioavailability, and improve the bioavailability in TCM preparations. We expect that the current study will be positive and informative.Entities:
Keywords: absorption enhancer; active constitutes identification; bio-pharmaceutics of TCMs preparations; evaluation system of bioavailability; pharmaceutical technologies
Mesh:
Substances:
Year: 2015 PMID: 26690115 PMCID: PMC4691079 DOI: 10.3390/ijms161226132
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The spectrum-effect relationships for Traditional Chinese medicines (TCMs).
Study on the spectrum-effect relationships for Traditional Chinese medicines (TCMs).
| Names | TCMs Composition | Fingerprint | Pharmacology | Experimentalmodel | Analytical Method | Active Components | Reference |
|---|---|---|---|---|---|---|---|
| - | HPLC-DAD-MS | Anti uric acid | Quails | CCA | Aesculin, chlorogenic acid, chicoric acid, isochlorogenic acid A/B/C and 13,14-seco-stigma5(6), 14(15)-diene-3α-ol | [ | |
| HPLC | Anti-inflammatory, immunosuppressive activities | mice spleen cells | GRA | Peak 5, peak 10 | [ | ||
| - | HPLC-PDA-ELSD | Anti-gastric effect | Mice, GES-1 cell | GRA | Ononin, astragaloside III, astragaloside IV | [ | |
| - | UPLC-PDA/HPLC-DAD | Antibacterial effect/Anti-MRSA activity/Anti-inflammatory | HCA, CCA, PCA, PLS | Berberine, jateorrhizine, palmatine, coptisine, epiberine | [ | ||
| Da Cheng Qi Tang | HPLC-DAD | Purgative effect | Mice | HCA | Hesperidin, aloe-emodin, honokiol, rhein, magnolol, emodin, sennoside A | [ | |
| - | HPLC-DAD-FICL | Anti-oxidant effect | H2O2 scavenging activities | CA | Piceid, resveratrol, torachrysone-8- | [ | |
| - | UPLC/MS, semi-preparative HPLC | Antibacterial effect | Agar-diffusion method; Broth microdilution method | - | Gallic acid, peak 6, peak 9–11 | [ | |
| - | IR | Antitumor effect | 7901, Hela cells | MLR | Nitidine chloride | [ | |
| - | HPLC-ELSD | NO inhibition | RAW264.7 cell | PLS | Peak 2, peak 4–6, peak 10, peak 12, peak 13 | [ | |
| - | UPLC-PDA | Anti-HIV activity(Ribonuclease H) | enzyme activity | BA | Catechin, epicatechin, aloe-emodinmonoglucoside, Peak (tR = 21.28 min) | [ | |
| - | HPLC-DAD | Antioxidant effect | DPPH radical scavenging | HCA | Delphinins, anthocyanidin-3-glucosides | [ | |
| EtOAC extracts of | - | HPLC-DAD | Antibacterial effect | HCA, MLR, PCA | Salicylic acid | [ | |
| - | UPLC-PDA | Antibacterial effect | CCA | Hypaconitine, peak 1, peak 3 | [ | ||
| - | UPLC-PDA | Anti-oxidative injury | H9c2 myocardial cell | BA | Peak 3–5, peak 11–14, peak 18, peak 19, peak 21–25 | [ | |
| Qizhiweitong Granules | HPLC-DAD | Promoting gastrointestinal motility | Small intestine smooth muscle cells | GRA, BP neural network | Naringin, neohesperidin, hesperidin, neoponcirin, narirutin, liquiritinapioside, albiflorin analogues, neoeriocitrin, glycyrrhizin | [ | |
| ZuoJin Wan | HPLC-DAD | Biothermo-logical effect | CCA | Evodiamine, palmatine hydrochloride, berberine hydrochloride | [ | ||
| Suanzaoren decoction | HPLC-PDA | Sedative effect | Mice | Correlation and regressive analysis | Spinosin, ferulic acid, mangiferin, glycyrrhizic acid, peak 3, peak 8, peak 9, peak 16, peak 21, peak 34, peak 42, peak 46, peak 47 | [ | |
| - | HPLC-MS/MS | Hemostatic activities | New Zealand rabbit | CCA | Cecarbon | [ | |
| - | HPLC | Anti-hepatic fibrosis | Mice | GRA, PLS, | Adenosine, calycosin | [ | |
| - | HPLC-DAD | Antioxidants | DPPH | MCA | Crocins-1, crocins-2, crocins-3 | [ | |
| - | HPLC-MS/MS | Hemostatic activities | New Zealand rabbit | CCA | Huaicarbon A, huaicarbon B | [ | |
| - | UPLC-ELSD | Mitochondria growth promoting effect | Rat | CCA | Mesaconitine, benzoylaconitine, benzoylhypacotine | [ | |
| - | UPLC-ELSD | Antibacterial effect | HCA, MLR, PCA | Cholic acid, taurocholate sodium, chenodeoxycholic acid | [ | ||
| - | HPLC-DAD | Hypoglycemic effect | Rat | - | Flavonoids (tectoridin, swertisin) | [ | |
| Da-Huang-Fu-Zi-Tang | UHPLC-ESI-Q-TOF-MS | Anti-acute pancreatitis effect | AR42J cell | CCA | Talatisamine, rhein glucoside, rhein isomer methylation, hypaconine, hydroxyl-chrysophanol, emodin glucuronide conjugation, chysophanol glucuronide conjugation | [ |
CCA: canonical correlation analysis; GRA: grey relational analysis; HCA: hierarchical cluster analysis; PCA: principal component analysis; PLS: partial least squares; MLR: Multiple linear regression ; BA: bivariate analysis ; BP: back propagation; MCA: multivariate correlation analysis; CE: capillary electrophoresis; IR: infrared spectroscopy; LC: liquid chromatography; UV: ultraviolet spectrometry; ELSD: evaporating light scattering detector; FICL: flow injection chemiluminescence; MS: mass spectrometry.
Figure 2The knock-in/knock-out model for TCMs (a, b, c, and d represent different components in TCMs).
Study on the knock-in and knock-out target components in TCMs.
| Names | Knock-in or Knock-out Components | Pharmacology | Experimental Model | Active Components | Reference |
|---|---|---|---|---|---|
| Berberine, palmatine, coptisine, epiberberine, jateorrhizine, columbamine | Growth inhibition of shigelladysenteriae | Microcalorimetry | Berberine, coptisine | [ | |
| Epimedin A, epimedin B, epimedin C, icariin | Cell proliferation, differentiation | Third generation rat osteoblasts | Epimedin A, epimedin B, epimedin C, icariin | [ | |
| Bilirubin, bilirubin conjugate, glycocholic acid, cholic acid, chenodeoxycholic acid, hyodeoxycholic acid, sodium taurocholic acid, deoxycholic acid | Inhibition of hydrogen peroxide-induced damage | SH-SY5Y | Bilirubin, bilirubin conjugate, glycocholic acid, cholic acid | [ | |
| Isochlorogenic acids, chlorogenic acid, flavones, iridoid glycosides | Anti-virus, anti-bacteria | Vero cell, | Isochlorogenic acids | [ | |
| Curcumin, demethoxycurcumin, bisdemethoxycurcumin | Anti-oxidant activity, anti-coagulant effect, anti-oxidant stress damage | DPPH, rabbit, PC12 | Curcumin > demethoxycurcumin > bisdemethoxycurcumin | [ | |
| Puerarin, daidzin, daidzein, compound X | Anti-oxidant damage | HUVEC | Puerarin, compound X | [ | |
| Shenmai formulae | Panoxadiol, panaxotriol, ophiopogonpolysaccharide, ophiopogonin | Antitumor effect | S180 bearing mice | Panoxadiol, panaxotriol, ophiopogonpolysaccharide | [ |
HUVEC: human umbilical vein endothelial cells; DPPH: 2,2-diphenylpicrylhydrazyl; PC12: pheochromocytoma.
Figure 3The pharmacokinetics (PK)-pharmacodynamics (PD) relationships for TCMs.
Study on the pharmacokinetics (PK)-pharmacodynamics (PD) relationships in TCMs.
| Names | TCMs Composition | PK Ingredients | PD | Analytical Method | Active Components | Reference |
|---|---|---|---|---|---|---|
| Da-Huang-Fu-Zi-Tang | Talatisamine emodin isomer | Anti-acute pancreatitis effect in AR42J cell | CCA | Talatisamin chysophanol glucuronide conjugation | [ | |
| Qingkailing injection | Baicalin, geniposide, cholalic acid, hyodeoxycholic acid, chlorogenic acid, neochlorogenic acid | Temperature changes in rat | Baicalin, geniposide | [ | ||
| Yin-Teng-Gu-Bi-Kang Precription | Tanshinone IIA | MDA in rat’s serum | Tanshinone IIA | [ | ||
| Shengmai injection | Ginsenoside (Rg1, Rb1) | NO in rat’s serum | Ginsenoside (Rg1, Rb1) | [ | ||
| — | Orcinol glucoside | SOD, GSH, GSH-PX in plasma | Orcinol glucoside | [ | ||
| — | Schisandrin, gomisin D, gomisin O, tigloylgomisin H, angeloylgomisin Q, gomisin G, gomisin B, angeloylgomisin P, schisantherin A, gomisin E, schisantherin D, deoxyschizandrin, gomisin R, γ-schisandrin, angeloylisogomisin O, angeloylgomisin O, 6- | ALT in rat’s serum | Schisandrin, schisantherin A, deoxyschizandrin, γ-schisandrin, 7-8-dihydroxy-schizandrin, PeaktR (42.0 min) | [ | ||
| — | Aloe Emodin, rhein, emodin, chrysophanol | Amylase, endotoxin, TNF-α, diamineoxidase in beagle dog’s serum; Temperature changes and NO in rat | Rhein | [ | ||
| Tea polyphenols | — | Epigallocatechingallate, epicatechingallate, epigallocatechin, epicatechin | MDA in rat’s liver | Epigallocatechi-n gallate, epicatechingallate, epigallocatechi-n, epicatechin | [ |
SOD: superoxide dismutase; GSH: glutathione; GSH-PX: glutathione peroxidase; ALT: alanine transaminase; MDA: malondialdehyde; AUE: area under efficacy; AUC: area under concentration. E: efficacy; C: concentration.
Figure 4The integrated pharmacokinetics for TCMs.
Study on the integrated pharmacokinetics in TCMs.
| Names | TCMs Composition | Integrated Ingredients | Integrated Method | Pharmacology | Correlation Analysis | Reference |
|---|---|---|---|---|---|---|
| - | Rhodojaponin (I, II, III) | Weighting factor based on | Myocardial damage (LDH, CK-MB) | - | [ | |
| - | Panax Notoginsenoside R1, Ginsenosides Rg1, Rb1, Re, Rd | - | - | [ | ||
| Huanglian-Zhizi couplet medicine | Gardenia acid, geniposide | Antioxidant efficacy (SOD) | [ | |||
| Huang-Lian-Jie-Du-Tang | Berberine, palmatine, baicalin, baicalein, geniposide | Anti-ischemia | - | [ | ||
| - | Schisandrin, schisantherin A, deoxyschisandrin, γ-schisandrin | Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) | [ | |||
| Jiao-Tai-Wan | Berberine, palmatine, coptisine, epiberberine, jatrorrhizine | - | - | [ | ||
| Huang-Lian-Jie-Du-Tang | Groenlandicine, berberine, palmatine, epiberberine, jatrorrhizine, columbamine | - | - | [ | ||
| Total coumarins in | - | Bergapten, imperatorin…isoimperatorin | - | - | [ | |
| Tea polyphenols | - | Epigallcocatechingallate, Epicatechingallate, Epigallocatechin, Epicatechin | Anti-lipid peroxidation | [ | ||
| Gegen-Qinlian Decoction | Puerarin, Daidzein, Baicalin, Baicalein, Wogonoside, Wogonin, Glycyrrhizin, Liquiritin, Berberine, Jateorhizine, Palmatine | - | - | [ |
LDH: lactate dehydrogenase; CK-MB: creatine kinase-measurement blood; E-C: effect-concentration.
Figure 5The applications of related pharmaceutical technologies for Chinese herbal monomers, extracts and compound. (a: bioadhesive polymers; b: mircoemulsion; c: self-microemulsion; d: nanosuspensions; e: polymer β-Cyclodextrin inclusion; f: polymeric micelles; g: liposomes; h: phospholipid complex; i: solid lipid nanoparticles; j: solid dispersion; k: micronization; l: absorption enhancer).
Figure 6The evaluation system of bioavailability establishment and related pharmaceutical technology applications for the Flos Lonicerae Japonicae-Fructus Forsythiae (FLJ-FF) herb couple (↑: improvement).
Figure 7The path for studying bio-pharmaceutics for TCM preparations (↑: improvement).